Tag Archives: VBL Therapeutics

March, 2015

• 25 March

  VBL Therapeutics’ Experimental Brain Cancer Drug Improves Survival in Phase 2 Study

  

  Israel’s VBL Therapeutics said that its experimental brain cancer drug met the main goal of improving overall survival in a mid-stage study. The company announced top-line interim results from its ongoing Phase II study of investigational VB-111 in patients with recurrent glioblastoma (rGBM). According to VBL, the drug demonstrated a …

  Share

  • Facebook
  • Twitter
  • LinkedIn

February, 2015

• 17 February

  VBL Therapeutics Stops Development of its Psoriasis and Ulcerative Colitis Candidate and Focuses on its Lead Cancer Drug

  

  Israel’s VBL Therapeutics announced that it does not plan to continue development of its VB-201 for treatment of patients with psoriasis and ulcerative colitis (UC). The company said that its Phase II studies evaluating its lead Lecinoxoid compound VB-201 in patients with psoriasis and UC did not meet their primary …

  Share

  • Facebook
  • Twitter
  • LinkedIn